Trial Profile
Comparison of the efficacy of peginterferon alfa-2a + ribavirin and no treatment for the prevention of liver disease in patients with chronic hepatitis C virus infections.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Apr 2011
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C; Liver dysfunction
- Focus Therapeutic Use
- Acronyms LOTOS
- 01 Apr 2011 New trial record